Amal Ltd | Annual Report 2022-23 Note 27.11 Loans Disclosures pursuant to the Regulation 34(3) read with para A of Schedule V to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section 186 (4) of the Companies Act, 2013. Particulars Purpose Amount outstanding as at Maximum balance during the year As at March 31, 2023 As at March 31, 2022 As at March 31, 2023 As at March 31, 2022 Subsidiary Company: Amal Speciality Chemicals Ltd For project expenditure and working capital requirement 1,699.00 2,202.00 6,699.14 2,202.00 During 2022-23, the loans aggregating ` 5,000.14 lakhs are converted into 27,19,000 equity shares at ` 110.34 per share amounting to ` 3,000.14 lakhs and 2,00,00,000, 10%non-cumulative redeemable preference shares at ` 10 per share, amounting to ` 2,000 lakhs. Note 27.12 Disclosure requirement under MSMED Act, 2006 The Company has certain dues to suppliers (trade and capital) registered under the Micro, Small and Medium Enterprises Development Act, 2006 (MSMEDAct). The disclosures pursuant to the saidMSMEDAct are as follows: (` lakhs) Particulars As at March 31, 2023 As at March 31, 2022 Principal amount due to suppliers registered under the MSMEDAct and remaining unpaid as at year end 10.69 1.69 Interest due to suppliers registered under theMSMEDAct and remaining unpaid as at year end - - Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year - - Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year - - Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year - - Interest due and payable towards suppliers registered under MSMED Act, for payments already made - - Further interest remaining due and payable for earlier years - -
RkJQdWJsaXNoZXIy MjA2MDI2